Compare AM & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AM | BMRN |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 10.9B |
| IPO Year | 2017 | 1999 |
| Metric | AM | BMRN |
|---|---|---|
| Price | $22.47 | $57.43 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 18 |
| Target Price | $22.50 | ★ $88.22 |
| AVG Volume (30 Days) | ★ 2.3M | 1.8M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.95% | N/A |
| EPS Growth | ★ 3.61 | N/A |
| EPS | 0.86 | ★ 1.80 |
| Revenue | $1,188,426,000.00 | ★ $1,313,646,000.00 |
| Revenue This Year | $4.92 | $14.30 |
| Revenue Next Year | $6.74 | $11.65 |
| P/E Ratio | ★ $26.49 | $31.21 |
| Revenue Growth | 7.43 | ★ 17.62 |
| 52 Week Low | $15.52 | $50.76 |
| 52 Week High | $23.84 | $66.28 |
| Indicator | AM | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 48.52 | 51.83 |
| Support Level | $22.45 | $56.32 |
| Resistance Level | $23.84 | $60.06 |
| Average True Range (ATR) | 0.55 | 1.31 |
| MACD | -0.18 | 0.27 |
| Stochastic Oscillator | 22.97 | 91.83 |
Antero Midstream Corp is a midstream company that owns, operates, and develops midstream energy assets that service Antero Resources' production and completion activity in the Appalachian Basin, located in West Virginia and Ohio. The company has two operating segments: the Gathering and Processing segment, which includes a network of gathering pipelines and compressor stations that collect and process production from Antero Resources wells in West Virginia and Ohio, and the Water Handling segment, which includes two independent systems that deliver water from sources including the Ohio River, local reservoirs, and several regional waterways. The company derives a majority of its revenue from the Gathering and Processing segment.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.